Search In this Thesis
   Search In this Thesis  
العنوان
Preparation of some radiolabeled pharmaceutical compounds for possible medical applications /
الناشر
Walaa Ibrahim Mohamed Elghareb ,
المؤلف
Walaa Ibrahim Mohamed Elghareb
هيئة الاعداد
باحث / Walaa Ibrahim Mohamed EL-Ghareb
مشرف / Ahmed Abd El-Bary
مشرف / Mina Ibrahim Tadros
مشرف / Ismail Taha Ibrahim
تاريخ النشر
2020
عدد الصفحات
161 P . :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
العلوم الصيدلية
تاريخ الإجازة
1/1/2020
مكان الإجازة
جامعة القاهرة - كلية الصيدلة - Pharmaceutical Sciences (Pharmaceutics)
الفهرس
Only 14 pages are availabe for public view

from 203

from 203

Abstract

This thesis is divided into a general introduction and three separate chapters that can be read independently. The general introduction is discussing the nuclear medicine application based radiopharmaceuticals and the incorporation of nanotechnology science as delivery vehicles with radiopharmaceutical design yielding radiopharmaceutical particulates. The first chapter is touching the development and characterization of gold nanoparticles as drug delivery vehicles and loading of anticancer agents to the formed gold nanoparticles. The second one is addressing the radiolabeling of the anticancer agents and investigating the stability of radiolabeled anticancer agents loaded to the gold nanoparticles. The third one is describing the in-vivo evaluation of the two prepared nano-sized radiopharmaceuticals in normal and solid tumor bearing mice. This is followed by complete reference list that is compiled in the end,immediately after the three chapters Radionuclides play an important role in nuclear medicine. When they are properly harnessed, these have valuable emission properties that can be used for diagnostic imaging techniques, such as single photon emission computed tomography (SPECT, e.g. 67Ga, 99mTc, 111In) and positron emission tomography (PET, e.g. 68Ga, 64Cu, 89Zr), as well as therapeutic applications (e.g. 47Sc, 177Lu, 90Y, 225Ac,). A fundamental critical component of a radiopharmaceutical is the ligand that binds the radionuclide so that, it can be properly directed to a desirable molecular target in-vivo. Hence, there is an urgent need to achieve efficacious and safe delivery of the radionuclide to the target organ with minimal non-specific uptake by healthy tissues. This can be achieved by the incorporation of nanoparticles (NPs) as delivery vehicles with radiopharmaceuticals design generating what is called nano-sized radiopharmaceuticals